PeptideScanner source updateshttps://peptidescanner.com/updates/Selected, source-linked peptide trial, regulatory, and safety records.en-usFDA proposes excluding three GLP-1 ingredients from the 503B bulks listhttps://peptidescanner.com/stories/fda-glp1-503b-bulks-list-proposal/https://peptidescanner.com/stories/fda-glp1-503b-bulks-list-proposal/FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the list of bulk substances that 503B outsourcing facilities may use for compounding.2026-07-29RegulatorySemaglutideTirzepatideLiraglutideFDA requests removal of a warning from certain GLP-1 drug labelshttps://peptidescanner.com/stories/fda-glp1-label-warning-removal-request/https://peptidescanner.com/stories/fda-glp1-label-warning-removal-request/FDA asked manufacturers to remove suicidal behavior and ideation warning language from certain semaglutide, tirzepatide, and liraglutide labels.2026-07-29SafetySemaglutideTirzepatideLiraglutideFDA warning letter names retatrutide and tirzepatide productshttps://peptidescanner.com/stories/fda-gram-peptides-warning-letter/https://peptidescanner.com/stories/fda-gram-peptides-warning-letter/FDA issued a warning letter to Gram Peptides that describes the agency's findings about products marketed with retatrutide and tirzepatide.2026-07-29RegulatoryRetatrutideTirzepatideFDA announces approval of a higher-dose semaglutide producthttps://peptidescanner.com/stories/fda-higher-dose-semaglutide-approval/https://peptidescanner.com/stories/fda-higher-dose-semaglutide-approval/FDA announced approval of a higher-dose Wegovy product, adding a regulatory event to the semaglutide profile's selected official records.2026-07-29RegulatorySemaglutideFDA committee met on seven peptide-related groups of bulk drug substanceshttps://peptidescanner.com/stories/fda-pcac-peptide-review-meeting/https://peptidescanner.com/stories/fda-pcac-peptide-review-meeting/FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.2026-07-29RegulatoryBPC-157EmideltideEpitalonKPVMOTS-cSemaxTB-500FDA details concerns with unapproved GLP-1 productshttps://peptidescanner.com/stories/fda-unapproved-glp1-concerns-record/https://peptidescanner.com/stories/fda-unapproved-glp1-concerns-record/FDA's public page describes agency concerns and actions involving unapproved versions of semaglutide and tirzepatide, with adverse-event information dated May 31, 2026.2026-07-29SafetySemaglutideTirzepatideBPC-157 hamstring study appears in trial registryhttps://peptidescanner.com/stories/bpc-157-hamstring-study-posted/https://peptidescanner.com/stories/bpc-157-hamstring-study-posted/ClinicalTrials.gov lists a recruiting BPC-157 study sponsored by Hudson Biotech.2026-07-22Clinical trialsBPC-157Cagrilintide pediatric study record updatedhttps://peptidescanner.com/stories/cagrilintide-pediatric-study-updated/https://peptidescanner.com/stories/cagrilintide-pediatric-study-updated/ClinicalTrials.gov lists a recruiting Cagrilintide study sponsored by Novo Nordisk A/S.2026-07-22Clinical trialsCagrilintideElamipretide Barth syndrome study record updatedhttps://peptidescanner.com/stories/elamipretide-barth-syndrome-study-updated/https://peptidescanner.com/stories/elamipretide-barth-syndrome-study-updated/ClinicalTrials.gov lists a recruiting Elamipretide study sponsored by Stealth BioTherapeutics Inc.2026-07-22Clinical trialsElamipretideMariTide bioavailability study record updatedhttps://peptidescanner.com/stories/maritide-bioavailability-study-updated/https://peptidescanner.com/stories/maritide-bioavailability-study-updated/ClinicalTrials.gov lists a completed Maridebart cafraglutide study sponsored by Amgen.2026-07-22Clinical trialsMaridebart cafraglutideMazdutide living-liver-donor study record postedhttps://peptidescanner.com/stories/mazdutide-liver-donor-study-posted/https://peptidescanner.com/stories/mazdutide-liver-donor-study-posted/ClinicalTrials.gov lists a Mazdutide study that is not yet recruiting sponsored by West China Hospital.2026-07-22Clinical trialsMazdutidePemvidutide IMPACT study record updatedhttps://peptidescanner.com/stories/pemvidutide-impact-study-updated/https://peptidescanner.com/stories/pemvidutide-impact-study-updated/ClinicalTrials.gov lists a completed Pemvidutide study sponsored by Altimmune, Inc.2026-07-22Clinical trialsPemvidutidePetrelintide combination study record postedhttps://peptidescanner.com/stories/petrelintide-combination-study-posted/https://peptidescanner.com/stories/petrelintide-combination-study-posted/ClinicalTrials.gov lists a Petrelintide study that is not yet recruiting sponsored by Hoffmann-La Roche.2026-07-22Clinical trialsPetrelintideRetatrutide renal-impairment study record updatedhttps://peptidescanner.com/stories/retatrutide-renal-impairment-study-updated/https://peptidescanner.com/stories/retatrutide-renal-impairment-study-updated/ClinicalTrials.gov lists an active, not recruiting Retatrutide study sponsored by Eli Lilly and Company.2026-07-22Clinical trialsRetatrutideSurvodutide liver-activity study record updatedhttps://peptidescanner.com/stories/survodutide-liver-activity-study-updated/https://peptidescanner.com/stories/survodutide-liver-activity-study-updated/ClinicalTrials.gov lists an active, not recruiting Survodutide study sponsored by Boehringer Ingelheim.2026-07-22Clinical trialsSurvodutide